P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy

Current estimates indicate that the hepatitis C (HCV) is the leading cause of mortality around the world, with infection rates steadily increasing in Egypt. The dual therapy for this silent epidemic with pegylated-interferon-α2b/ribavirin has markedly improved the success rates in genotype-4 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd-Rabou, Ahmed A., Eskander, Emad F., Mohamed, Mervat S., Yahya, Shaymaa M.M., Sherbini, Ashraf El, Shaker, Olfat G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150111/
https://www.ncbi.nlm.nih.gov/pubmed/30258864
http://dx.doi.org/10.1016/j.gendis.2015.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150111/
https://www.ncbi.nlm.nih.gov/pubmed/30258864
http://dx.doi.org/10.1016/j.gendis.2015.02.004

Ejemplares similares